July 24^th, 2019: EMA Grants Myelo Therapeutics Orphan Drug Designation for Myelo001 as Treatment for Acute Radiation Syndrome.

Dec 4^th, 2018: Positive Data on Efficacy of Myelo001 in treating Acute Radiation Syndrome published in Blood.

Sep 25^th, 2018: FDA Grants Myelo Therapeutics Orphan Drug Designation for Myelo001 as Treatment for Acute Radiation Syndrome.

March 1^st, 2018: Myelo Therapeutics has been selected as a finalist of the Lyfebulb-Helsinn Innovation Summit Award in Oncology..

Nov 8^th, 2017: Interview on progress of Myelo001 development program and Myelo Therapeutics experience with Elsevier’s “The Hive” incubator program.

Oct 4^th, 2017: Myelo Therapeutics’ Phase II study of Myelo001 in Chemotherapy-induced Neutropenia is fully recruited.

June 20^th, 2017: Myelo Therapeutics conducts successful Pre-IND meeting with U.S. Food and Drug Administration (FDA) for Myelo001 and completes new financing round.

Jan 16^th, 2017: New data published in Blood confirms that the chemo-protective effect of Myelo001 is specific to healthy tissue.

Jan 13^th, 2017: Myelo Therapeutics is selected as one of four companies worldwide to participate in Elsevier's incubator project.

Apr 7^th, 2016: First patient treated in MyeloConcept Phase IIa study of Myelo001 in Chemotherapy-Induced Neutropenia.

Feb 26^th, 2016: Start of MyeloConcept Phase IIa study of Myelo001 in Chemotherapy-Induced Neutropenia.

Dec 15^th, 2015: "Myelo Therapeutics Receives Approval to Start Phase II of Myelo001 in Chemotherapy-induced Neutropenia and Closes Series B Financing Round".